Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer

Abstract The third most prevalent type of epidermal growth factor receptor (EGFR) mutation, EGFR exon 20 insertions (EGFRex20ins), involves 2%–12% of all cases of EGFR‐positive non‐small cell lung cancer (NSCLC). Approximately 90% of the mutations occur within the loop structure region, and the most...

Full description

Bibliographic Details
Main Authors:	Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zhan
Format:	Article
Language:	English
Published:	Wiley 2023-11-01
Series:	Thoracic Cancer
Subjects:	EGFR exon 20 insertions epidemiology non‐small lung cancer targeted therapy
Online Access:	https://doi.org/10.1111/1759-7714.15127

Similar Items

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
by: Arsela Prelaj, et al.
Published: (2022-06-01)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
by: Zhang SS, et al.
Published: (2021-07-01)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
by: Pedro E.N.S. Vasconcelos, MS, et al.
Published: (2021-03-01)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
by: Samy Chelabi, et al.
Published: (2021-10-01)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
by: Pacini L, et al.
Published: (2021-03-01)

<i>EGFR</i> Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
by: Laura Pacini, et al.
Published: (2022-01-01)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
by: Waleed Kian, et al.
Published: (2022-09-01)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
by: Timothée Olivier, et al.
Published: (2022-09-01)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
by: Xuesong Chen, et al.
Published: (2023-02-01)

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
by: Yue Zheng, et al.
Published: (2023-11-01)

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets
by: Santiago Viteri, et al.
Published: (2023-02-01)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
by: YanRu Qin, et al.
Published: (2020-08-01)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
by: Ikei S. Kobayashi, et al.
Published: (2021-12-01)

Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
by: Xue YANG, et al.
Published: (2022-05-01)

Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report
by: Jaemin Kim, BS, et al.
Published: (2023-12-01)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
by: Jiabao Hou, et al.
Published: (2022-04-01)

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
by: Chao Shi, et al.
Published: (2022-09-01)

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
by: Mahlet Z. Tamirat, et al.
Published: (2021-03-01)

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
by: Oliver Illini, et al.
Published: (2024-04-01)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
by: Sai-Hong Ignatius Ou, MD, et al.
Published: (2023-10-01)

Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer
by: Wensheng ZHOU, et al.
Published: (2020-02-01)

Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
by: Shun Matsuura, et al.
Published: (2020-01-01)

Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab
by: Elena Corral de la Fuente, et al.
Published: (2022-03-01)

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
by: Vishal Shah, et al.
Published: (2023-03-01)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
by: Yurong Wang, et al.
Published: (2021-11-01)

Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)
by: Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
Published: (2023-05-01)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
by: Huamao M. Lin, PhD, et al.
Published: (2022-03-01)

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
by: Pedro E.N.S. Vasconcelos, MS, et al.
Published: (2020-09-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01)

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
by: Maximilian J. Hochmair, et al.
Published: (2024-01-01)

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
by: Giulio Metro, et al.
Published: (2022-07-01)

Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
by: Muhammad Harbi Praditya, et al.
Published: (2023-01-01)

First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient  with EGFR Exon 20 Insertion Mutantion
by: Zhengguo LI, et al.
Published: (2024-03-01)

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
by: Guangjian Yang, et al.
Published: (2023-01-01)

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
by: Petrini I, et al.
Published: (2022-10-01)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with <i>EGFR</i> Exon 20 Insertion Mutations
by: Giulio Metro, et al.
Published: (2021-04-01)

EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
by: Ramakrishna R. Sompallae, et al.
Published: (2023-05-01)

Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)
by: Camil Ciprian MIRESTEAN, et al.
Published: (2022-09-01)

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
by: Josette Kamel, BA, et al.
Published: (2021-11-01)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
by: Arnold A, et al.
Published: (2023-07-01)